Clinical Trial Update: Empagliflozin Reduces Progression of Diabetic Retinopathy in Patients With High Risk of Diabetic Macular Edema [Phase 4]

View source ↗

Summary

Phase 4 trial update assessing empagliflozin for reducing progression of diabetic retinopathy in high-risk patients with diabetic macular edema.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Macular Edema
• Diabetic Retinopathy
• Type 2 Diabetes Mellitus

Drugs mentioned

• Empagliflozin (empagliflozin)

Snippet

Sponsor: Hannover Medical School | Conditions: Diabetes Mellitus, Type II | Phase 4 | Status: TERMINATED